We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The effect of adjunctive telmisartan treatment on psychopathology and cognition in patients with schizophrenia.
- Authors
Fan, X.; Song, X.; Zhao, M.; Jarskog, L. F.; Natarajan, R.; Shukair, N.; Freudenreich, O.; Henderson, D. C.; Goff, D. C.
- Abstract
Objective This study examined the effect of adjunctive telmisartan on psychopathology and cognition in olanzapine- or clozapine-treated patients with schizophrenia. Method In a 12-week randomized, double-blind, placebo-controlled study, patients diagnosed with schizophrenia or schizoaffective disorder received either telmisartan (80 mg once per day) or placebo. Psychopathology was assessed using the Positive and Negative Syndrome Scale ( PANSS) and the Scale for Assessment of Negative Symptoms ( SANS), and a neuropsychological battery was used to assess cognitive performance. Assessments for psychopathology and cognition were conducted at baseline and week 12. Results Fifty-four subjects were randomized, and 43 completed the study (22 in the telmisartan group, 21 in the placebo group). After 12-weeks of treatment, the telmisartan group had a significant decrease in PANSS total score compared withthe placebo group (mean ± SD: - 4.1 ± 8.1 vs. 0.4 ± 7.5, P = 0.038, SCohen's d = 0.57). There were no significant differences between the two groups in change from baseline to week 12 in PANSS subscale scores, SANS total score, or any cognitive measures ( P > 0.100). Conclusion The present study suggests that adjunctive treatment with telmisartan may improve schizophrenia symptoms. Future trials with larger sample sizes and longer treatment durations are warranted.
- Subjects
PATHOLOGICAL psychology; PEOPLE with schizophrenia; SCHIZOPHRENIA treatment; COGNITION; OLANZAPINE; CLOZAPINE; THERAPEUTICS
- Publication
Acta Psychiatrica Scandinavica, 2017, Vol 136, Issue 5, p465
- ISSN
0001-690X
- Publication type
Article
- DOI
10.1111/acps.12799